Exploring 'decision regret' in adjuvant‐treated melanoma patients: Results from a cross‐sectional survey on 200 participants.

The study explored the concept of 'decision regret' in melanoma patients who underwent adjuvant therapy with nivolumab, pembrolizumab, or dabrafenib and trametinib. The primary objective was to assess the percentage of patients who regretted their decision to undergo adjuvant treatment, with a secondary objective of identifying factors associated with 'decision regret'. Factors such as age, side effects, and perceived treatment success influenced patients' regret levels. Shared decision-making with physicians was found to reduce regret, highlighting the importance of comprehensive patient counseling. [Extracted from the article]